Regal Partners’s Radiopharm Theranostics RADX Stock Holding History

Regal Partners’s Portfolio RADX Stock Details RADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$168K	Hold	40,138	–	–	0.01%	122
2026 Q1	$173K	Sell	40,138 -50,771	-56%	-$248K	0.01%	106
2025 Q4	$475K	Hold	90,909	–	–	0.03%	86
2025 Q3	$502K	Hold	90,909	–	–	0.04%	65
2025 Q2	$422K	Hold	90,909	–	–	0.04%	50
2025 Q1	$437K	Hold	90,909	–	–	0.04%	39
2024 Q4	$408K	Buy	+90,909	New	+$598K	0.04%	49

Other funds holding RADX

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

HSBC Holdings London, United Kingdom $239B AUM 42.32% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Regal Partners's RADX Position: Q2 2026 in Review

Regal Partners held its Radiopharm Theranostics (RADX) position steady in Q2 2026 at 40,138 shares worth $168K. The position accounts for 0.01% of the portfolio, ranked #122.

Regal Partners first reported a position in RADX in Q4 2024 and has held it in 7 quarters since. The position peaked at $502K in Q3 2025. 6 funds tracked by Wall St. Rank hold RADX as of Q2 2026.

Regal Partners held 40,138 shares of Radiopharm Theranostics worth $168K as of Q2 2026.
Regal Partners left its Radiopharm Theranostics share count unchanged in Q2 2026.
Radiopharm Theranostics made up 0.01% of Regal Partners's portfolio in Q2 2026, its #122 holding.
Regal Partners first reported a position in Radiopharm Theranostics in Q4 2024 and has held it in 7 quarters since.
Regal Partners's Radiopharm Theranostics position peaked at $502K in Q3 2025.
6 funds tracked by Wall St. Rank held Radiopharm Theranostics as of Q2 2026.

Based on Regal Partners's 13F filing for Q2 2026, filed 14 Aug 2026.